Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482518 | 1.00 | TRPV1 (0.46) | TRPV1EGFREPHX2KDM4EALDH1A1 | |
| SCHEMBL25377441 | 0.86 | EPHX2 (0.47) | TRPV1EPHX2 | |
| SCHEMBL30482543 | 0.86 | EPHX2 (0.47) | TRPV1EPHX2 | |
| SCHEMBL30519339 | 0.86 | KIF11 (0.51) | TRPV1EGFREPHX2KCNH2SCN9A | |
| SCHEMBL25340913 | 0.86 | KIF11 (0.51) | TRPV1EGFREPHX2KCNH2SCN9A | |
| SCHEMBL25378159 | 0.83 | TRPV1 (0.43) | TRPV1EGFREPHX2 | |
| SCHEMBL25377798 | 0.83 | TRPV1 (0.46) | TRPV1EPHX2 | |
| SCHEMBL30482575 | 0.81 | KCNQ3 (0.47) | TRPV1EPHX2 | |
| SCHEMBL25378382 | 0.81 | KCNQ3 (0.47) | TRPV1EPHX2 | |
| SCHEMBL25378719 | 0.81 | TRPV1 (0.42) | TRPV1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |